Abstract | INTRODUCTION: Pulmonary toxicity of delayed onset is a rare complication of B-lymphocyte depleting antibody therapy and has been almost exclusively reported in older patients with B-cell malignancies. AIMS: To describe a pediatric patient with rituximab-associated lung injury (RALI), to systematically analyze previous reports of pulmonary complications, and to summarize common clinico-pathological features, treatment, and outcome. RESULTS: CONCLUSIONS:
|
Authors | Martin Bitzan, Mark Anselmo, Lucy Carpineta |
Journal | Pediatric pulmonology
(Pediatr Pulmonol)
Vol. 44
Issue 9
Pg. 922-34
(Sep 2009)
ISSN: 1099-0496 [Electronic] United States |
PMID | 19681063
(Publication Type: Case Reports, Journal Article, Review, Systematic Review)
|
Copyright | Copyright 2009 Wiley-Liss, Inc. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Rituximab
|
Topics |
- Adolescent
- Antibodies, Monoclonal
(adverse effects)
- Antibodies, Monoclonal, Murine-Derived
- Cryptogenic Organizing Pneumonia
(chemically induced)
- Humans
- Lung Injury
(chemically induced)
- Lymphocyte Depletion
(adverse effects)
- Male
- Rituximab
|